Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. - Wikidata - awgldk - TriplyDB

Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

http://www.wikidata.org/entity/Q33735589

about

Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Determination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimaging.Update in Tuberculosis/Pulmonary Infections 2015 A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)Tuberculosis therapy for 2016 and beyond.Early interventions for diabetes related tuberculosis associate with hastened sputum microbiological clearance in Virginia, USA.Determination of plasma concentrations of levofloxacin by high performance liquid chromatography for use at a multidrug-resistant tuberculosis hospital in Tanzania.Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model Importance of Drug Pharmacokinetics at the Site of Action Update in Mycobacterium tuberculosis lung disease 2014.Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study Physiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans.Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure.High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.Mycobacterium tuberculosis: 2014 Clinical trials in review Synthetic investigational new drugs for the treatment of tuberculosis.Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children.Emerging drugs and alternative possibilities in the treatment of tuberculosis.New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response.Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.AJRCCM: 100-Year Anniversary. Focus on Tuberculosis.Shortening Tuberculosis Treatment With Fluoroquinolones: Lost in Translation?Medium matters: modeling the impact of solid medium performance on tuberculosis trial sample size requirements Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes.Erratum: daily rifapentine for treatment of pulmonary tuberculosis: a randomized, dose-ranging trial.Reply to Alffenaar et al.Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?A Pilot Study of Immune Activation and Rifampin Absorption in HIV-Infected Patients without Tuberculosis Infection: A Short Report.Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury: a prospective cohort study.Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data.Delayed Sputum Conversion in TB-HIV Co-Infected Patients with Low Isoniazid and Rifampicin Concentrations.Reply to Chang et al., "Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?"Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer

P2860

Q26771997-60DE47F0-612A-4340-A747-F1D62E62EB06 Q27324299-E7C0B797-2F4B-4AA3-A948-63E70CCEFFAB Q28387739-7A44D6DB-C6F1-4240-AB72-459919E61CD6 Q28602112-1EED5BDF-7C6C-455D-A8E0-DB1BDEE32621 Q30248788-7B711830-816D-4C07-98BC-A15ED5DA5284 Q30274831-1CAAF83D-2365-4E7E-8CE1-914A32A63575 Q30274875-E0462F72-AFFC-4486-A426-8A4008036D11 Q30379233-AF764623-E721-4BD1-960E-813D7712A825 Q33648045-EE946EAF-5A11-4CF3-AC39-6A0BD912BEE9 Q33735642-D030D4EE-022A-44AA-AB94-0EC742E6647C Q35607718-3CB984E6-7DC3-42AA-AFD1-8306BA494706 Q35867681-E62B4442-6A2E-4DFC-9484-7D6A20817A83 Q36012300-DDEFA4C5-82C9-4765-A97D-3D398BFADFD5 Q36036963-C722BB31-B0C0-4FA2-849B-7513208CACF8 Q37120003-781F109F-F457-4F3A-B05B-282626EC1C32 Q37434341-D3364089-D0F7-470D-91AE-F824989EAC3A Q37507802-7FC1487C-5F55-4F5A-A03C-905E417B89FD Q38387116-C00279F3-5F9F-455F-932E-06520D81E589 Q38635790-9F516EA2-AB6C-49F0-904D-E0D54943DFA5 Q38673843-A6B6C863-6028-4C29-BB60-BECB8EB0DAE9 Q38724073-784D7F9B-5BD7-4374-B6E4-8CA26F792B17 Q38754367-0FF24887-5E54-416D-B8EF-CAAC5B1CF986 Q38851434-3A9AA4E3-6BD9-4FA6-B10B-FEE2066D3EE4 Q40095703-58D53B5A-4A6C-4D47-A497-E46061797A32 Q40192322-FA8F0505-AFD8-4CA6-ABF7-4002811A0E7F Q40220575-5ACA44C1-F4F1-46E0-8D43-E679ACBDE83B Q40363572-EED4C74F-43EB-4DE7-9EA6-DA78ED1AF607 Q40711897-75588C0C-A2A2-475B-A1E6-B82A9A64BF1F Q42281128-19945079-F5CB-4C40-968F-5C77400812D6 Q42340846-B03158B4-2C10-4820-A6A3-CDC41679A11D Q45237067-ACC35A73-2B75-4D81-A04A-8E2B02C4CEED Q47332682-F558DAF7-F36C-4859-BDD3-4731ED4C4071 Q50048262-36CD358B-D9EF-4821-AA7F-B1089F57883E Q51542639-1182AF1E-D481-4075-B9FE-CE34AD0BDC84 Q52606539-6493101F-3F7B-483E-AF7E-F6C1C8D0B827 Q52669182-0C7456E6-F7C9-4490-8767-21113DC55448 Q54296806-CC05FA31-9AD8-41EB-99DD-26D7C6DA20CE Q58785246-E1446434-6159-43E5-9FC1-DEB77E73B5D6

P2860

Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

http://www.wikidata.org/entity/Q33735589

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Daily rifapentine for treatmen ...... andomized, dose-ranging trial.

@ast

Daily rifapentine for treatmen ...... andomized, dose-ranging trial.

@en

type

label

Daily rifapentine for treatmen ...... andomized, dose-ranging trial.

@ast

Daily rifapentine for treatmen ...... andomized, dose-ranging trial.

@en

prefLabel

Daily rifapentine for treatmen ...... andomized, dose-ranging trial.

@ast

Daily rifapentine for treatmen ...... andomized, dose-ranging trial.

@en

P1433

Q33735589-21528473-67B2-42E6-BB78-5A299AFCA4CF

P1476

Q33735589-EE451AB4-183C-4709-9327-DB491BC450D5

P2093

Q33735589-037E95E0-FC16-4EBC-95D0-47D31307592E

Q33735589-06A603B1-9396-4540-ABF5-3AF072360988

Q33735589-0965A9BD-0292-46CC-9F91-1F0577F889F2

Q33735589-19C90ECB-7E20-44C6-A3F5-DE9579689FF0

Q33735589-503EE5BE-81C8-4CA4-9E45-164061F5E59C

Q33735589-8E3DE44D-90F0-4E35-90AD-967F4D3736C9

Q33735589-99A0A046-9B74-402E-929B-CC17E1855E19

Q33735589-9DAB4A59-B59B-4391-B1B4-865CC2628A28

Q33735589-9E38F1BE-EFD9-44E2-92B9-EF0647FEB91B

Q33735589-A4B90830-33A3-430E-A2EE-5DA2E77759D4

P2860

Q33735589-25C9DB70-DF2C-4828-9431-4A4D35A548FF

Q33735589-2CADD1F6-ADA4-47B5-9FA7-DFCEC9558E9C

Q33735589-3460D60D-8010-49F3-B6C5-01809BC998BC

Q33735589-34947535-8C70-48FA-9750-C0EEB041E068

Q33735589-3CA10DBB-9AE1-4B26-B5E9-909BDDB150E8

Q33735589-3E827052-AAE3-4FA0-BB5D-2E17EEB6A9C6

Q33735589-43F5E558-5372-4779-AA34-25084FF15A51

Q33735589-4B19D398-4D31-4F13-8D72-B1DC8483C95B

Q33735589-4CC0603F-7481-4143-859A-988045619A9C

Q33735589-59C50415-5638-4BC0-B62A-8395DF35D7BF

P304

Q33735589-E540156A-67F2-474E-B3CC-A81112DC5738

P31

Q33735589-DD2E8D24-7567-4767-9EFD-0856344E0594

P356

Q33735589-285B8C5A-FED0-4656-930C-286710464CCC

P407

Q33735589-766D880D-85D1-4E72-9FAE-B2397DC0B835

P433

Q33735589-069B7468-F6A0-4AC2-B11E-CAAD2457570E

P478

Q33735589-EB918B87-C9B0-40BE-9284-D8A64E2AEBF5

P50

Q33735589-91C24D07-BC49-4124-AB52-ED6DA097CC8A

Q33735589-9AC71C09-3312-4071-8AF6-1CC17FF98F82

Q33735589-D321288D-397C-4A19-8DFD-E18A9058FCFD

P577

Q33735589-32E9FF15-A05F-4695-B975-03266FA3A2B7

P698

Q33735589-9A39D946-CC1C-4354-ACE7-F657D398F943

P921

Q33735589-37312EFE-BE17-4205-9068-7DFF9D0090FB

P932

Q33735589-0E7356BD-E3D3-4308-A97B-4E2249C44016

P356

RCCM.201410-1843OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Daily rifapentine for treatmen ...... randomized, dose-ranging trial

@en

P2093

Andrew Vernon

http://www.w3.org/2001/XMLSchema#string

Emily J Hecker

http://www.w3.org/2001/XMLSchema#string

Eric L Nuermberger

http://www.w3.org/2001/XMLSchema#string

Grace Muzanyi

http://www.w3.org/2001/XMLSchema#string

John L Johnson

http://www.w3.org/2001/XMLSchema#string

Kelly E Dooley

http://www.w3.org/2001/XMLSchema#string

Lorna Bozeman

http://www.w3.org/2001/XMLSchema#string

Marc Weiner

http://www.w3.org/2001/XMLSchema#string

Neil Schluger

http://www.w3.org/2001/XMLSchema#string

Pei-Jean I Feng

http://www.w3.org/2001/XMLSchema#string

P2860

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model

Role of individual drugs in the chemotherapy of tuberculosis

Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis

Two-sided confidence intervals for the single proportion: comparison of seven methods

Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

Exact and Asymptotic Weighted Logrank Tests for Interval Censored Data: The interval R package.

Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

P304

333-343

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.201410-1843OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

191

http://www.w3.org/2001/XMLSchema#string

P50

Charles M. Heilig

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25489785

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

5447287

http://www.w3.org/2001/XMLSchema#string